Vanda Pharmaceuticals Inc. logo

Vanda Pharmaceuticals Inc. (VM4)

Market Closed
19 Jun, 06:04
XFRA XFRA
3. 92
+0.06
+1.55%
- Market Cap
18.48 P/E Ratio
0% Div Yield
0 Volume
-0.01 Eps
3.86
Previous Close
Day Range
3.92 3.92
Year Range
3.46 5.9
Want to track VM4 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 10 days

Summary

VM4 closed Thursday higher at €3.92, an increase of 1.55% from Wednesday's close, completing a monthly increase of 4.26% or €0.16. Over the past 12 months, VM4 stock lost -14.78%.
VM4 is not paying dividends to its shareholders.
The last earnings report, released on May 07, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Jul 29, 2025.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

VM4 Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates

Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.07 per share a year ago.

Zacks | 2 months ago
Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript

Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript

Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Kevin Moran - SVP, CFO & Treasurer Mihael Polymeropoulos - Founder, President, CEO & Chairman Conference Call Participants Charles Duncan - Cantor Fitzgerald Raghuram Selvaraju - H.C. Wainwright Andrew Tsai - Jefferies Operator Hello, and thank you for standing by.

Seekingalpha | 5 months ago
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates

Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates

Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.04 per share a year ago.

Zacks | 5 months ago

Vanda Pharmaceuticals Inc. Dividends

VM4 is not paying dividends to its shareholders.

Vanda Pharmaceuticals Inc. Earnings

30 Jul 2025 (In 1 week) Date
-
Cons. EPS
-
EPS
29 Jul 2025 (In 1 week) Date
-
Cons. EPS
-
EPS
7 May 2025 Date
-
Cons. EPS
-
EPS
6 May 2025 Date
-
Cons. EPS
-
EPS
5 Feb 2025 Date
-
Cons. EPS
-
EPS
VM4 is not paying dividends to its shareholders.
30 Jul 2025 (In 1 week) Date
-
Cons. EPS
-
EPS
29 Jul 2025 (In 1 week) Date
-
Cons. EPS
-
EPS
7 May 2025 Date
-
Cons. EPS
-
EPS
6 May 2025 Date
-
Cons. EPS
-
EPS
5 Feb 2025 Date
-
Cons. EPS
-
EPS

Vanda Pharmaceuticals Inc. (VM4) FAQ

What is the stock price today?

The current price is €3.92.

On which exchange is it traded?

Vanda Pharmaceuticals Inc. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is VM4.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, no market cap data is available.

When is the next earnings date?

The next earnings report will release on Jul 29, 2025.

Has Vanda Pharmaceuticals Inc. ever had a stock split?

No, there has never been a stock split.

Vanda Pharmaceuticals Inc. Profile

Biotechnology Industry
Healthcare Sector
Mihael H. Polymeropoulos CEO
XFRA Exchange
US9216591084 ISIN
US Country
368 Employees
- Last Dividend
- Last Split
12 Apr 2006 IPO Date

Overview

Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for addressing high unmet medical needs on a global scale. With a focus on conditions that affect sleep-wake disorders, schizophrenia, and a variety of other medical conditions, Vanda Pharmaceuticals seeks to improve the quality of life for patients worldwide. Since its incorporation in 2002, and headquartered in Washington, D.C., the company has made significant strides in bringing novel treatments to the market and continues to expand its robust pipeline of promising therapeutic candidates.

Products and Services

  • HETLIOZ (tasimelteon) – Marketed for the treatment of non-24-hour sleep-wake disorders. The pipeline for HETLIOZ includes potential applications for:
    • Jet lag disorder
    • Insomnia
    • Delayed sleep phase disorder
    • Sleep disturbances in autism spectrum disorder
    • Pediatric Non-24
  • Fanapt (iloperidone) oral tablets – Marketed for the treatment of schizophrenia, with ongoing development for:
    • Bipolar I disorder
    • Parkinson's disease psychosis
    • A long-acting injectable (LAI) formulation for schizophrenia
  • Tradipitant (VLY-686) – A small molecule neurokinin-1 receptor (NK-1R) antagonist in development for:
    • Gastroparesis
    • Motion sickness
    • Atopic dermatitis
    • COVID-19 pneumonia
  • VTR-297 – A small molecule histone deacetylase inhibitor being studied for:
    • Hematologic malignancies
    • Various oncology indications
  • VQW-765 – A small molecule nicotinic acetylcholine receptor partial agonist under investigation for:
    • Performance anxiety
    • Psychiatric disorders
  • VHX-896 – An active metabolite of iloperidone in development.
  • Antisense Oligonucleotide Molecules – Under investigation for various indications.
  • Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activators and Inhibitors, including:
    • VSJ-110 for the treatment of dry eye and ocular inflammation
    • VPO-227 for treating secretory diarrhea disorders such as cholera

Contact Information

Address: 2200 Pennsylvania Avenue NW
Phone: 202 734 3400